QLT, Inc. (NASDAQ: QLTI), a global biopharmaceutical company, has dedicated their efforts to discovering, developing and commercializing novel therapies. The company’s research and development efforts are focused on the field of ophthalmology. QLT leverages its three unique technology platforms, photodynamic therapy, Atrigel® and punctal plugs with drugs, to develop products such as Visudyne® and Eligard® and future product opportunities. For further information, visit the Company’s web site at www.qltinc.com.
- 18 years ago
QualityStocks
QLT, Inc. (NASDAQ: QLTI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…